Dr. Sartor on Sipuleucel-T in mCRPC

Video

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

The analysis was focused on African Americans as compared with Caucasians. Unlike many prior studies, there was a positive effect for African-American—treated patients, explains Sartor. This study demonstrated that African Americans see more of a benefit with sipuleucel-T based on the PROCEED registry report.

The study matched 420 Caucasians with 210 African Americans, making a 2:1 match looking at all prostate-specific antigen (PSA) scores, states Sartor. A multivariate analysis was investigated to determine that African Americans would continue to have the effect when other factors, such as hemoglobin and alkaline phosphate were taken into account.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD